Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Common Equity (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Common Equity for 11 consecutive years, with $4.4 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 30.88% to $4.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 billion through Dec 2025, up 30.88% year-over-year, with the annual reading at $4.4 billion for FY2025, 30.88% up from the prior year.
  • Common Equity for Q4 2025 was $4.4 billion at BeOne Medicines, up from $4.1 billion in the prior quarter.
  • The five-year high for Common Equity was $6.1 billion in Q4 2021, with the low at $3.3 billion in Q4 2024.
  • Average Common Equity over 5 years is $4.1 billion, with a median of $3.8 billion recorded in 2023.
  • The sharpest move saw Common Equity skyrocketed 58.5% in 2021, then decreased 28.52% in 2022.
  • Over 5 years, Common Equity stood at $6.1 billion in 2021, then dropped by 28.52% to $4.4 billion in 2022, then decreased by 19.3% to $3.5 billion in 2023, then fell by 5.8% to $3.3 billion in 2024, then surged by 30.88% to $4.4 billion in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $4.4 billion, $4.1 billion, and $3.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.